drugset / Trial / NCT00606060

BAY14-2222 Continuous Infusion in Surgeries

NCT00606060

Phase 3 Completed 15 enrolled Bayer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase III study, to evaluate the efficacy and safety of continuous infusion of rFVIII-FS in the treatment of patients with hemophilia A undergoing major elective surgery by achieving the required therapeutic concentrations.

Timeline

Start
2004-07
Primary completion
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ADVATE Protein / enzyme biologic 100 iu
Subject ADVATE Protein / enzyme biologic 400 iu

Indications